Screener
Iovance Biotherapeutics, Inc. IOVA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
FAQ
- What is Iovance Biotherapeutics, Inc.'s EPS (diluted)?
- Iovance Biotherapeutics, Inc. (IOVA) reported EPS (diluted) of -$0.11 in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Iovance Biotherapeutics, Inc.'s EPS (diluted) increased by 66.7% year-over-year, from -$0.33 to -$0.11.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2024), Iovance Biotherapeutics, Inc.'s EPS (diluted) has grown at a -16.6% compound annual growth rate (CAGR), from -$2.22 to -$1.29.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Iovance Biotherapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude